HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Comella, C. L. Search for Related Content PubMed PubMed Citation Articles by Comella, C. L.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Restless legs syndrome

Treatment with dopaminergic agents

From the Movement Disorder Section, Department of Neurological Sciences, Rush Medical Center, Chicago, IL.

Address correspondence and reprint requests to Cynthia L. Comella, MD, Movement Disorder Section, Department of Neurological Sciences, Rush Medical Center, 1725 West Harrison, Suite 755, Chicago, IL 60612; e-mail: ccomella{at}rush.edu

Restless legs syndrome (RLS) is a common neurologic disorder that affects 5 to 10% of the population and increases in prevalence with aging. The clinical hallmarks of RLS include dysesthesias or paresthesias in the legs and sometimes the arms, occurring primarily at rest, which are usually worse in the evening and are alleviated by movement. RLS can be a disabling disorder, causing sleep disturbance at night and excessive sleepiness during the day. Although treatment with levodopa alleviates symptoms, many RLS patients develop rebound (occurrence of symptoms during the night) or augmentation (occurrence of symptoms before levodopa dosing in the evening). Augmentation occurs in up to 82% of patients treated with levodopa, limiting the long-term usefulness of this agent. The direct dopamine receptor agonists are long-acting drugs often administered as a single dose at bedtime. Among these agents, pergolide, pramipexole, ropinirole, and cabergoline have all been shown to alleviate RLS symptoms in 70 to 100% of patients. The most common adverse effect is nausea. Augmentation, although it may be associated with chronic agonist use, is usually mild and responsive to additional dosing. The direct dopamine receptor agonists have largely replaced levodopa as the most effective treatment for RLS.

This article has been cited by other articles:

				K. Turner III, M. Ozaki, D. Hayes Jr, A. Harahsheh, K. Moltz, K. Chintala, S. Knazik, D. Kamat, and D. Dunnigan Index of Suspicion Pediatr. Rev., June 1, 2006; 27(6): 231 - 237. [Full Text] [PDF]

				M. J. Thorpy New paradigms in the treatment of restless legs syndrome Neurology, June 28, 2005; 64(12_suppl_3): S28 - S33. [Abstract] [Full Text] [PDF]